Home/Pipeline/Lead Asset (undisclosed)

Lead Asset (undisclosed)

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Engimmune Therapeutics

About Engimmune Therapeutics

Engimmune Therapeutics is a private, preclinical-stage biotech focused on developing off-the-shelf soluble TCR engagers for oncology and autoimmune diseases. The company's core strength lies in its integrated AI-guided protein engineering and laboratory platforms, designed to overcome historical challenges in soluble TCR development like affinity, stability, and safety. Backed by leading life science investors Novo Holdings and Pureos Bioventures, Engimmune is advancing a preclinical lead asset and a broader pipeline, positioning itself in the competitive but high-potential field of targeted immunotherapy.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed